ArticleFrontiers in immunology2026
Xiaoyao San alleviates emotional distress - induced TNBC growth through augmenting intratumoral CD8
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emotional distress (ED) is closely associated with the progression of triple-negative breast cancer (TNBC). Xiaoyao San (XYS), a classical Chinese herbal prescription traditionally used for mood regulation, has demonstrated potential therapeutic efficacy in emotion-related breast cancer. However, the molecular mechanisms through which XYS mitigates ED-induced TNBC (ED-TNBC) remain insufficiently characterized. This study aimed to investigate the therapeutic effects of XYS on ED-TNBC and elucidate its underlying molecular mechanisms. Methods: A TNBC mouse model subjected to chronic unpredictable mild stress (CUMS) was developed to simulate ED-TNBC conditions. The therapeutic efficacy of XYS at varying doses was evaluated through behavioral assessments and tumor growth analyses. Multi-omics analyses integrating network pharmacology, bioinformatics, and molecular dynamics simulations were employed to identify principal active constituents and key molecular targets of XYS. Transcriptomic profiling, Results: High-dose XYS markedly alleviated depression-like behaviors and suppressed ED-TNBC tumor progression, with no evident adverse effects observed. Transcriptomic and molecular analyses revealed that XYS enhanced CD8 Conclusion: XYS directly targets and activates the intratumoral Rela/NF-κB-Cxcl9 axis, promoting CD8
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.